Bora Pharmaceuticals, a contract development and manufacturing organization, completed the acquisition of Upsher-Smith Laboratories, a generics manufacturer, from Sawai Group, a Japan-based company mainly engaged in the manufacture and sale of medical and over-the-counter drugs, and Sumitomo, a trading company, for $210m. “This is a significant milestone for Bora Group, marking the most critical expansion of Bora’s presence in the US market and significantly enhancing Bora’s position as a global competitor with regard to its CDMO business and commercial Rx business,” Bobby Sheng, Bora Chairman and CEO.